Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLx-2101 in Hypertension
NCT00562549Phase 2Completed
- Sponsor
- Retension Pharmaceuticals
- Start
- Jul 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) comparing SLx-2101 with Matching Placebo Dose (2 arms). Primary endpoints: Systolic Blood Pressure at 12 days and Diastolic Blood Pressure at 12 days. Started Jul 2007; status: completed.
02
Drugs
slx-2101
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00562549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562549.